文献速递脑血管病

血栓长度对THERAPY试验中动脉内抽吸取栓结局的影响

Impact of Thrombus Length on Outcomes After Intra-Arterial Aspiration Thrombectomy in the THERAPY Trial.
PubMed 文献 · Stroke · 2017-06-08

THERAPY试验的事后分析纳入108例前瞻性测量血栓长度≥8 mm的大血管闭塞卒中患者,评估血栓长度与抽吸取栓疗效的关系。结果显示血栓越长,90天临床结局越差,但抽吸取栓相对于单纯静脉r-tPA的相对获益可能更大。

要点

  • 血栓长度每增加5 mm,90天mRS不良结局风险增加(OR 1.24)。
  • 血栓越长,症状性出血、严重不良事件和死亡风险越高。
  • 血栓越长,抽吸取栓相对于单纯静脉r-tPA的治疗效应可能更大。

核心结论

  • 血栓较长的大血管闭塞卒中患者90天临床结局更差,但抽吸取栓相对于单纯静脉r-tPA可能具有更大的相对获益。

研究设计与样本

  • THERAPY试验的事后分析,纳入108例前瞻性测量血栓长度≥8 mm的大血管闭塞卒中患者。

主要发现

  • 血栓长度中位数14.0 mm(四分位距9.7-19.5 mm),28%为颈内动脉、62%为M1、10%为M2。
  • 血栓长度每增加5 mm,90天mRS不良结局的OR为1.24(95%CI 1.04-1.52,P=0.02),校正后P=0.004。
  • 血栓越长与严重不良事件(校正P=0.01)、症状性出血(校正P=0.03)和死亡(校正P=0.01)增加相关。
  • 血栓长度与血管造影再灌注(mTICI 2b-3)无显著关系,但与血管内操作时间延长相关(ρ=0.36,P=0.045)。
  • 血栓长度增加与抽吸取栓治疗效应增大相关(交互作用P=0.03)。

关键数值与推荐

  • 血栓长度每增加5 mm,90天mRS不良结局OR 1.24(95%CI 1.04-1.52,P=0.02)。
  • 血栓长度与严重不良事件校正P=0.01、症状性出血校正P=0.03、死亡校正P=0.01相关。
  • 血栓长度与血管内操作时间相关(ρ=0.36,P=0.045)。
  • 血栓长度与抽吸取栓治疗效应的交互作用P=0.03。

临床怎么用

  • 对血栓较长的大血管闭塞卒中患者,抽吸取栓相对于单纯静脉r-tPA可能带来更大的相对获益。
  • 血栓长度可作为评估抽吸取栓相对获益的参考因素。

局限性

  • 本研究为THERAPY试验的事后分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Increasing thrombus length (TL) impedes recanalization after intravenous (IV) thrombolysis. We sought to determine whether the clinical benefit of aspiration thrombectomy relative to IV r-tPA (recombinant tissue-type plasminogen activator) may be greater at longer TL. METHODS: THERAPY was a randomized trial of aspiration thrombectomy plus IV r-tPA versus IV r-tPA alone in large-vessel stroke patients with prospective TL measurement ≥8 mm. In this post hoc study, we evaluated the association of TL with trial end points and potential endovascular treatment effect, using univariate, multivariable, and multiplicative interaction analyses. RESULTS: TL data were available for all 108 patients (28% internal carotid artery, 62% M1, and 10% M2). Median TL was 14.0 mm (interquartile range, 9.7-19.5 mm). Longer TL was associated with worse outcome (90-day modified Rankin Scale score: odds ratio, 1.24 per 5-mm TL increment; 95% confidence interval, 1.04-1.52; P=0.02), even after adjusting for key outcome predictors (adjusted P=0.004). Longer TL was also associated with more serious adverse events (adjusted P=0.01), more symptomatic hemorrhages (adjusted P=0.03), and increased mortality (adjusted P=0.01). No significant relationship was observed between TL and angiographic reperfusion (modified thrombolysis in cerebral ischemia 2b-3), but greater TL was associated with longer endovascular procedural times (ρ=0.36; P=0.045). Increasing TL was associated with greater aspiration thrombectomy treatment effect (interaction term P=0.03). This might be related to a potentially stronger adverse effect of increasing TL on 90-day modified Rankin Scale for patients treated with IV r-tPA (ρ=0.39; P=0.01) compared with intra-arterial therapy (ρ=0.20; P=0.165). CONCLUSIONS: Ischemic stroke patients with longer symptomatic thrombi have worse 90-day clinical outcomes but may have a greater relative benefit of aspiration thrombectomy over IV r-tPA alone. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01429350.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Yoo AJ, Khatri P, Mocco J, et al. Impact of Thrombus Length on Outcomes After Intra-Arterial Aspiration Thrombectomy in the THERAPY Trial. Stroke. 2017. PMID: 28596447. doi:10.1161/STROKEAHA.116.016253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。